|
 |
  |
 |
 |
 |
|
 |
 |
|
 |
Basel, 29 April 2008
Genentech and Biogen
Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Dear
Investor, Genentech and Biogen Idec announced today top-line results from a phase II/III
clinical study of Rituxan in Systemic Lupus Erythematosus. Roche has not opted in to this indication,
however we wanted to make sure you are aware of this release.
View
the press release |
 |
|
 |
|
|